1
|
Vollbach K, Tenbrock K, Wagner N, Horneff G, Klein A, Foeldvari I, Haas JP, Aries P, Gauler G, Striesow F, Hoff P, Scholz C, Tatsis S, Seipelt E, Klotsche J, Minden K. Outcome of adult patients with JIA treated with the biosimilar Benepali ®: results of the biologic register JuMBO. Arthritis Res Ther 2022; 24:271. [PMID: 36514116 PMCID: PMC9746218 DOI: 10.1186/s13075-022-02968-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 12/02/2022] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND To analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali® (Biogen Inc, Cambridge, USA). METHODS Data from the prospective registry, JuMBO (Juvenile arthritis MTX/Biologics long-term Observation), were used for the analysis. JuMBO is a long-term observational cohort study. It follows adult patients with JIA who were formerly included in the national JIA biologic register (BiKeR Registry). Both registries provide individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with disease-modifying anti-rheumatic drugs (DMARDs). RESULTS Eighty-three patients from the German JuMBO registry were treated with Benepali®. Of these, 74% had switched from Enbrel® (Pfizer Inc., NYC, USA) the originator of etanercept to Benepali® for cost reasons. Therapy survival of patients treated with Benepali® in comparison to Enbrel® in patients matched by significant parameters was comparable. Adverse events (AE) were reported in 25.3% and serious adverse events (SAE) in 9.6% of patients. Physicians rated no SAE causative related to Benepali®. The majority of SAEs were surgical/medical procedures and there was only one infection. All efficacy parameters (cJADAS-10, Physician Global Assessment, number of joints with active arthritis, patients' overall well-being, pain, and HAQ) demonstrated improvement over 24 months (p-values were not significant). 9.6% of patients permanently discontinued Benepali® because of an AE. CONCLUSIONS Tolerability and effectiveness of the biosimilar Benepali® were satisfactory and therapy survival was comparable to the originator. Further data on therapy with biologics and biosimilars such as Benepali® must be collected by registries such as BiKeR and JuMBO in order to optimize therapy and patient outcomes and to reduce costs in the health system in the long term.
Collapse
Affiliation(s)
- Kristina Vollbach
- grid.412301.50000 0000 8653 1507Department of Pediatrics, RWTH Aachen University Hospital, Aachen, Germany
| | - Klaus Tenbrock
- grid.412301.50000 0000 8653 1507Department of Pediatrics, RWTH Aachen University Hospital, Aachen, Germany
| | - Nobert Wagner
- grid.412301.50000 0000 8653 1507Department of Pediatrics, RWTH Aachen University Hospital, Aachen, Germany
| | - Gerd Horneff
- Centre for Pediatric Rheumatology, Department of Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany ,grid.411097.a0000 0000 8852 305XDepartment of Pediatric and Adolescent Medicine, University Hospital of Cologne, Cologne, Germany
| | - Ariane Klein
- Centre for Pediatric Rheumatology, Department of Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany ,grid.411097.a0000 0000 8852 305XDepartment of Pediatric and Adolescent Medicine, University Hospital of Cologne, Cologne, Germany
| | - Ivan Foeldvari
- Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany
| | - Johannes-Peter Haas
- German Centre for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
| | - Peer Aries
- Rheumatologie im Struenseehaus, Hamburg, Germany
| | | | | | - Paula Hoff
- MVZ Endokrinologikum Berlin am Gendarmenmarkt, Berlin, Germany
| | | | - Stefanie Tatsis
- grid.491928.f0000 0004 0390 3635Marienkrankenhaus, Hamburg, Germany
| | - Eva Seipelt
- grid.473656.50000 0004 0415 8446Immanuel Krankenhaus, Berlin Buch, Germany
| | - Jens Klotsche
- grid.418217.90000 0000 9323 8675Deutsches Rheuma-Forschungszentrum Berlin, Leibniz Association, Berlin, Germany
| | - Kirsten Minden
- grid.418217.90000 0000 9323 8675Deutsches Rheuma-Forschungszentrum Berlin, Leibniz Association, Berlin, Germany ,grid.6363.00000 0001 2218 4662Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| |
Collapse
|
2
|
Throm S, Hömke R. [New antirheumatics : Advances for patients and society]. Z Rheumatol 2018; 77:290-296. [PMID: 29728806 DOI: 10.1007/s00393-018-0453-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The current repertoire of conventional, biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) presents wide-ranging options to help patients with inflammatory rheumatic diseases. These therapeutic possibilities have improved quality of life for many patients and also had a positive impact at the societal level. Among these positive effects are a reduction in short-term inability to work and early retirement; for paediatric patients they represent an opportunity for an almost normal school life including physical education. The development of formulations adapted to patients' needs has greatly facilitated the long-term treatment of these chronic diseases. Further additions to the therapeutic spectrum can be expected in the years to come, including new oral synthetic DMARDs. Even for rare inflammatory rheumatic diseases, various therapeutic options should be available soon, thus increasing these patients' chances of a life with significantly fewer impairments. As German trial sites are participating in many clinical trials on inflammatory rheumatic diseases, there are many opportunities to mediate patients to a trial if the approved treatment options do not prove satisfactory.
Collapse
Affiliation(s)
- S Throm
- Verband Forschender Arzneimittelhersteller e. V. (vfa), Hausvogteiplatz 13, 10117, Berlin, Deutschland
| | - R Hömke
- Verband Forschender Arzneimittelhersteller e. V. (vfa), Hausvogteiplatz 13, 10117, Berlin, Deutschland.
| |
Collapse
|
3
|
Barth S, Schlichtiger J, Hartmann B, Bisdorff B, Michels H, Radon K, Hügle B, Walsh L, Haas JP. Incidence of malignancies in patients with juvenile idiopathic arthritis: A retrospective single-center cohort study in Germany. Mod Rheumatol 2016; 27:60-65. [DOI: 10.1080/14397595.2016.1204711] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Swaantje Barth
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany,
| | - Jenny Schlichtiger
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany,
| | - Barbara Hartmann
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany,
| | - Betty Bisdorff
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany,
| | - Hartmut Michels
- German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, and
| | - Katja Radon
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany,
| | - Boris Hügle
- German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, and
| | - Linda Walsh
- Medical Physics Group, Institute of Physics, Science Faculty, University of Zürich, Zürich, Switzerland
| | - Johannes-Peter Haas
- German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, and
| |
Collapse
|
4
|
Niewerth M, Minden K, Klotsche J, Horneff G. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care]. Z Rheumatol 2015; 73:532-40. [PMID: 25096586 DOI: 10.1007/s00393-014-1378-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The majority of patients with juvenile idiopathic arthritis (JIA) need specialized care when they enter adulthood. An increasing number of these patients take biologic disease modifying antirheumatic drugs (DMARDs) at the time of transition. The biologic register BiKeR provides information about the health status and healthcare situation of JIA patients during childhood and adolescence and with their entrance into adulthood these patients are systematically transferred to JuMBO, the follow-up register for young adults with JIA treated with biologics and nonbiologic DMARDs. OBJECTIVE The aim of this study was to investigate the healthcare situation of patients with JIA during transition from pediatric to adult care. METHODS The current analyses included patients who were successfully transferred from the BiKeR to JuMBO registers. The DMARD treatment and patient-reported outcome (i.e. disease activity, pain and functional ability) were assessed at the last documentation in BikeR and at the first as well as the last documentation in JuMBO. RESULTS During the transition period 1 in 10 JIA patients stopped DMARD therapy and 1 in 20 patients did not visit a physician for adults. Three-quarters of the adult JIA patients included in JuMBO (N = 811) reached adult rheumatology care. Adult rheumatologists usually continued therapy with biologics in these patients. Every second patient was still being treated with etanercept, 5 years after the start of the first treatment with biologics. Adult rheumatologists changed the biologic substance in every fourth patient, mainly because of treatment failure. In comparison to patients in regular adult rheumatology care, those who did not remain in specialized care had a higher discontinuation rate of biologics. Moreover, patients with sporadic use of medical care had a significantly poorer health status than those with a regular use of medical care at least every 6 months. CONCLUSION The data show that there is a need for improving healthcare during the period of transition from pediatric to adult rheumatology.
Collapse
Affiliation(s)
- M Niewerth
- Deutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland,
| | | | | | | |
Collapse
|